文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于嵌合抗原受体 T 细胞的免疫疗法和放射疗法:潜力、前景和风险。

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks.

机构信息

Department of Radiation Oncology, Inselspital, Bern University Hospital, Freiburgstrasse 8, Bern, 3008, Switzerland.

Department for Biomedical Research, Radiation Oncology, University of Bern, Murtenstrasse 35, Bern, 3008, Switzerland.

出版信息

Mol Cancer. 2023 May 12;22(1):82. doi: 10.1186/s12943-023-01775-1.


DOI:10.1186/s12943-023-01775-1
PMID:37173782
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10176707/
Abstract

CAR T cell-based therapies have revolutionized the treatment of hematological malignancies such as leukemia and lymphoma within the last years. In contrast to the success in hematological cancers, the treatment of solid tumors with CAR T cells is still a major challenge in the field and attempts to overcome these hurdles have not been successful yet. Radiation therapy is used for management of various malignancies for decades and its therapeutic role ranges from local therapy to a priming agent in cancer immunotherapy. Combinations of radiation with immune checkpoint inhibitors have already proven successful in clinical trials. Therefore, a combination of radiation therapy may have the potential to overcome the current limitations of CAR T cell therapy in solid tumor entities. So far, only limited research was conducted in the area of CAR T cells and radiation. In this review we will discuss the potential and risks of such a combination in the treatment of cancer patients.

摘要

近年来,嵌合抗原受体 T 细胞(CAR T)疗法已经彻底改变了白血病和淋巴瘤等血液系统恶性肿瘤的治疗模式。与血液系统癌症的成功相比,CAR T 细胞在实体瘤中的治疗仍然是该领域的一个主要挑战,目前克服这些障碍的尝试尚未成功。放射治疗已被用于治疗各种恶性肿瘤数十年,其治疗作用从局部治疗到癌症免疫治疗的启动剂不等。放射治疗与免疫检查点抑制剂的联合应用已经在临床试验中取得了成功。因此,放射治疗的联合应用可能有潜力克服 CAR T 细胞疗法在实体瘤中的当前局限性。到目前为止,在 CAR T 细胞和放射治疗领域的研究还很有限。在这篇综述中,我们将讨论这种联合治疗在癌症患者治疗中的潜力和风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d6/10176707/7ab8bc7897b5/12943_2023_1775_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d6/10176707/7ab8bc7897b5/12943_2023_1775_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7d6/10176707/7ab8bc7897b5/12943_2023_1775_Fig1_HTML.jpg

相似文献

[1]
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks.

Mol Cancer. 2023-5-12

[2]
Therapeutic potential of CAR T cell in malignancies: A scoping review.

Biomed Pharmacother. 2022-2

[3]
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.

Front Immunol. 2022

[4]
"Hurdles race for CAR T-cell therapy in digestive tract cancer".

Immunol Rev. 2023-11

[5]
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.

Transfus Med Rev. 2019-2-14

[6]
Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.

Front Immunol. 2022

[7]
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.

Stem Cell Res Ther. 2021-3-29

[8]
Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies.

Adv Exp Med Biol. 2019

[9]
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.

J Exp Clin Cancer Res. 2022-3-31

[10]
Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.

Expert Opin Biol Ther. 2021-2

引用本文的文献

[1]
Can We Use CAR-T Cells to Overcome Immunosuppression in Solid Tumours?

Biology (Basel). 2025-8-12

[2]
Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles.

Nat Commun. 2025-8-4

[3]
Enhancing adoptive cell therapy: future strategies for immune cell radioprotection in neuro-oncology.

NPJ Precis Oncol. 2025-7-29

[4]
Tracking cellular therapies to optimize homing against liver metastases.

Front Immunol. 2025-6-25

[5]
Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives.

Mol Cancer. 2025-7-7

[6]
CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors.

Vaccines (Basel). 2025-6-19

[7]
Advancing liver cancer treatment with dual-targeting CAR-T therapy.

J Nanobiotechnology. 2025-6-24

[8]
The mechanisms and clinical significance of CD8 T cell exhaustion in anti-tumor immunity.

Cancer Biol Med. 2025-6-10

[9]
Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancer.

Neurooncol Adv. 2025-3-19

[10]
Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience.

Curr Oncol. 2025-3-17

本文引用的文献

[1]
Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma.

Discov Oncol. 2023-3-16

[2]
Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review.

Ann Transl Med. 2022-12

[3]
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours.

Nat Rev Clin Oncol. 2023-1

[4]
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect.

Nat Cancer. 2022-11

[5]
Tumor buster - where will the CAR-T cell therapy 'missile' go?

Mol Cancer. 2022-10-19

[6]
Exploiting radiation immunostimulatory effects to improve glioblastoma outcome.

Neuro Oncol. 2023-3-14

[7]
Immunomodulatory effects of carbon ion radiotherapy in patients with localized prostate cancer.

J Cancer Res Clin Oncol. 2023-7

[8]
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.

Nat Med. 2022-10

[9]
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer.

J Immunother Cancer. 2022-9

[10]
Siglec receptors as new immune checkpoints in cancer.

Mol Aspects Med. 2023-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索